ClinicalTrials.gg
TerminatedNCT01381562Updated Nov 29, 2017Results posted

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

A Phase 2 interventional study of Drug: GSK2251052 and Meropenem in Infections, Intestinal, sponsored by GlaxoSmithKline. Terminated at 31 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-29.

Primary conditionIntraabdominal InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Intraabdominal Infections
Why
  1. The study's title name Intraabdominal Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Microbiological findings of resistance on therapy in patients with complicated urinary tract infection

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Intraabdominal Infections with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Intraabdominal Infections · United States.

Enrollment
22nd of 24
15 · median 144
Started
2011
with 3 others
Phase 2
9 of 29
1 open now
Registered
7th of 29
by date
Lead sponsor
1 of 29
GlaxoSmithKline

Among the 29 studies in Intraabdominal Infections with a site in United States, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2011, is one of 9 in phase 2, and was the 7th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

3 of the 29 studies in Intraabdominal Infections with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Intraabdominal Infections with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use in the treatment of subjects with cIAI. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cIAI.

03

Conditions studied

  • Infections, Intestinal

Browse trials for

Keywords

  • intra-abdominal infection
  • belly
  • Gram-negative pathogen
  • abscess
  • peritonitis
04

In context

Intraabdominal Infections Reclassified

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

This study's enrollment of 15 is below the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.

Browse Intraabdominal Infections studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Intraabdominal Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects least 18 years of age.

N.B. Females of non-childbearing or may be enrolled. It is not to enrol females of childbearing potential; however, females of childbearing potential must have a negative pregnancy test at study entry and must have practiced adequate for at least 30 days prior to study entry. Additionally, the subject agrees to one of the following methods for avoidance of pregnancy during the entire study treatment period:

  • Abstinence; or,
  • Oral Contraceptive, either combined estrogen/progesterone or progesterone alone, PLUS an additional barrier method [ie, condom, occlusive cap (diaphragm or cervical/vault caps) or vaginal spermicidal agent (foam/gel/film/cream/suppository)]; or,
  • Injectable progesterone; or
  • Implants of levonorgestrel; or,
  • Estrogenic vaginal ring; or,
  • Percutaneous contraceptive patches; or
  • Intrauterine device (IUD) or intrauterine system (IUS) showing that failure rate is less than 1% in the IUD or IUS product label; or,
  • Has a male partner who is sterilized (vasectomy with documentation of azoospermia).
  • Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
  • Females are considered to be of non-childbearing potential if they have documented tubal ligation or hysterectomy; or are , defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol \< 40 pg/ml (\<147 pmol/L) is confirmatory]
  • Subject has evidence of a systemic inflammatory response believed to be related to an intra-abdominal infectious process with no evidence of another infectious source (e.g., catheter related, lung, urinary tract)
  • Subject has an abnormal white blood cell count (>12,000/µL or \<4,000/µL or >10% bands) PLUS one or more of the following
  • Fever, defined as >38°C oral, >38.5°C tympanic or >39°C rectal, within the last 24 hours
  • Heart rate of more than 90 beats per minute
  • Respiratory rate of more than 20 breaths per minute or a PaCO2 level of less than 32 mm Hg
  • Altered mental status thought due to an infectious process
  • Subject is post-op and required surgery within the last 24 hours prior to first dose of study medication OR subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or percutaneous drainage of an abscess) within 24 hours of first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis.
  • Subject has a known Gram-negative pathogen(s) isolated prior to study entry or a suspected Gram-negative post-operative infection or has failed a prior Gram negative treatment regimen

A subject enrolled as a failure of a previous antibacterial treatment regimen must:

Show lack of improvement or worsening in signs and symptoms of infection, including continued or worsening peritoneal findings Require additional surgical intervention which must be performed within 24 hours of first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis AND/OR Be post-op and have required surgery within 24 hours prior to first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis.

Have a culture positive for a Gram-negative pathogen (from an intra-abdominal site) N.B. Such subjects may be enrolled before the results of the culture are known but if the culture is negative, the subject must be removed from study drug therapy.

  • Subject requires antibacterial therapy for an anticipated duration of 7 days or more, in addition to surgical intervention, for one of the following eligible diagnoses:
  • Cholecystitis (including gangrenous cholecystitis) with rupture, perforation or progression of the infection beyond the gallbladder wall
  • Diverticular disease with perforation or abscess
  • Appendiceal perforation with duration of symptoms >=48 hours AND imaging that is strongly suggestive of free fluid or abscess
  • Acute gastric and duodenal perforations, only if operated more than 24 hours after perforation occurred
  • Traumatic perforation of the intestine only if operated more than 12 hours after perforation occurred
  • Peritonitis due to perforated viscus, post-operative, or other focus of infection (but not spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites)
  • Inflammatory bowel disease or ischemic bowel disease with bowel perforation
  • If pre-operative, subject must have peritoneal findings highly suspicious for cIAI, defined as one or more of the following:
  • Abdominal pain and/or tenderness
  • Localized or diffuse abdominal wall rigidity
  • An imaging procedure, ie. ultrasound or CT scan showing evidence of IAI
  • Mass
  • Ileus
  • or QTcF \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block

Exclusion criteria

Exclusion Criteria:

  • Subject has a known or suspected diagnosis of the following:
  • Abdominal wall abscess
  • Small bowel obstruction or ischemic bowel disease without perforation
  • Traumatic bowel perforation with surgery within 12 hours
  • Perforation of gastroduodenal ulcer with surgery within 24 hours
  • Any other intra-abdominal processes in which the primary etiology is not likely to be infectious.
  • Simple cholecystitis
  • Gangrenous or suppurative cholecystitis without rupture or extension beyond the gallbladder wall
  • Simple appendicitis
  • Acute suppurative cholangitis
  • Infected, necrotizing pancreatitis, or pancreatic abscess
  • Subject must not be managed by staged abdominal repair or open abdominal technique
  • Subject is known at study entry, prior to randomization to study medication, to have a cIAI caused by a Gram-positive pathogen or a pathogen resistant to the study antimicrobial agent.
  • Subject has an APACHE II score >20.
  • Subject is considered unlikely to survive the 4 6 week study period or has any rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock).
  • Subject requires treatment with concomitant systemic antibacterial agents other than vancomycin.
  • Subject has moderate to severe impairment of renal function including a calculated (CrCl) of less than 50 mL/min; requirement for peritoneal dialysis, hemodialysis, or hemofiltration; or oliguria (less than 20 mL urine output per hour over 24 hours).
  • Subject has a prior history of seizures or CNS abnormality and/or is using concomitant medications with seizure potential
  • Subject requires probenecid or valproic acid medications
  • Subject has evidence of known or pre-existing severe hepatic disease( score of B or C)
  • Subject has a known baseline less than 10 g/dL ,hematocrit less than 30% and/or a known reticulocyte count of >5% (ie, reticulocytes >5% of total RBC mass)
  • Subject has known neutropenia or is anticipated to develop neutropenia during the course of the study (ie, new chemotherapy patient), with less than 1000 cells/mm3
  • Subject has a known count less than 75,000 cells /mm3 (subjects with platelet counts as low as 50,000 cells /mm3 are eligible if the reduction is historically stable)
  • Subject has an immunocompromising illness; including known (HIV) infection or acquired immunodeficiency syndrome (AIDS), organ (including bone marrow) transplant recipients, and hematological , and therapy , including high-dose (e.g., greater than 40mg prednisone or equivalent per day for greater than two weeks)
  • Subject has participated in any drug or device study within 30 days of study entry or within 5 half-lives, whichever is longer.
  • Subject has had more than 24 hours of systemic antibacterial therapy for cIAI within the 48 hour period prior to first dose of IV study drug therapy, unless there is a documented lack of clinical response to such therapy
  • Subject has a history of moderate or severe to Meropenem or to beta-lactam antibiotics
  • Subject has previously received treatment with GSK2251052
  • Subject is pregnant or nursing.
  • Subject, in the opinion of the investigator, may be significantly compromised by a potential drop in haemoglobin greater than 2.5g/dl which is not related to the condition under study
  • French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    GSK2251052 750mg

    q12h administered via IV infusion, plus saline placebo

    Drug: Drug: GSK2251052 · Other: Placebo

  • Experimental
    GSK2251052 1500mg

    q12h administered via IV infusion, plus saline placebo

    Drug: Drug: GSK2251052 · Other: Placebo

  • Active comparator
    Meropenem 1G

    q8h administered via IV infusion, plus saline placebo

    Drug: Meropenem · Other: Placebo

Interventions

  • Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion

  • Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion

    Also known as: Merrem ®, Meronem

  • OtherPlacebo

    saline placebo

07

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event

    AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE included AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition

    Time frame: Up to Day 42

  2. Number of Participants With Clinically Significant Trends in Vital Signs Over the Period of Study Duration

    Vital parameters including systolic and diastolic blood pressure, heart rate, respiration rate, and temperature were recorded. The number of participants with potentially clinically concern value of any vital parameter at any visit were reported.

    Time frame: Up to Day 42

  3. Number of Participants With Normal and Abnormal ECG Findings

    12-lead ECGs was obtained during the study using an ECG machine and performed with the participant in a semi-supine position rested in this position for at least 10 minutes beforehand. Measurements deviated substantially from previous readings were repeated immediately. Number of participants with normal and abnormal ECG findings were reported.

    Time frame: Up to Day 42

  4. Laboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration

    Absolute mean hemoglobin values recorded over the period of duration were reported.

    Time frame: Up to Day 42

  5. Laboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration

    Absolute mean reticulocytes values recorded over the period of duration were reported.

    Time frame: Up to 42 days

  6. Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop

    Participants in whom the hemoglobin level dropped by more than 30% from Baseline that was not attributable to acute blood loss were recorded and immediately withdrawn from study treatment. Baseline assessments were recorded on Visit 1 (Day 1) and used as Baseline values. The change from Baseline was calculated by subtracting the Baseline values from Day 42 values. If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing. The mean change from Baseline in hemoglobin for participants with significant hemoglobin drop were reported.

    Time frame: Baseline (Day 1) and up to Day 42

  7. Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Intent to Treat (MITT) Population

    Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.

    Time frame: Day 5 to 9 post IV therapy

Secondary outcomes

  1. Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Evaluable Population.

    Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.

    Time frame: Day 5 to 9 post IV therapy

  2. Number of Participants With Microbiological Response in MITT Population

    Microbiological Response at End of IV Therapy was assessed as Microbiological Success (MS) or Microbiological Failure (MF). MS was categorized as microbiological eradication (ME) and presumed microbiological eradication (PME). MF was categorized as microbiological persistence (MP), presumed microbiological persistence (PMP), unable to determine, new infection and colonization. Number of participants with microbiological response in MITT population were reported.

    Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

  3. Number of Participants With Microbiological Response in Microbiological Evaluable Population

    Microbiological Response at End of IV Therapy was assessed as MS or MF. MS was categorized as ME and PME. MF was categorized as MP and PMP, unable to determine, new infection and colonization. Number of participants with microbiological response in microbiological evaluable population were reported.

    Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

  4. Number of Participants With Clinical Response in Microbiological Evaluable Population

    Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.

    Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

  5. Number of Participants With Clinical Response in MITT Population

    Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.

    Time frame: End of IV therapy (0-24 hours post-therapy) and Late Follow-up (21-28 days post-therapy)

  6. Number of Participants With Therapeutic Response in Microbiological Evaluable Population

    Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.

    Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

  7. Number of Participants With Therapeutic Response in MITT Population

    Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.

    Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

  8. Maximum Plasma Concentration (Cmax) of GSK2251052

    Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for pharmacokinetics (PK) analysis was not collected.

    Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  9. Area Under the Concentration Time Curve (AUC) of GSK2251052

    AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  10. Time to Cmax (Tmax) of GSK2251052

    Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  11. Cmax of GSK2251052 Using Non-intensive PK Sampling

    Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  12. AUC of GSK2251052 Using Non-intensive PK Sampling

    AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  13. Tmax of GSK2251052 Using Non-intensive PK Sampling

    Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  14. Cmax of GSK2251052 Using Intensive PK Sampling

    Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

  15. AUC of GSK2251052 Using Intensive PK Sampling

    AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

  16. Tmax of GSK2251052 Using Intensive PK Sampling

    Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

    Time frame: Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

08

Results

Posted Nov 29, 2017
Limitations and caveats
This study was terminated early because only 15 participants were enrolled.

Participant flow

The study was conducted at five centers in four countries (United Stated of America, Spain, France and Russia) between 03-October-2011 and 05-March-2012.

Participant flow — Overall Study
MilestoneGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1.0 g
Started545
Completed535
Not completed010
Withdrew: Adverse event010

Outcome measures

PrimaryNumber of Participants With Any Adverse Event

AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE included AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Event
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Any AE543
Any SAE230
PrimaryNumber of Participants With Clinically Significant Trends in Vital Signs Over the Period of Study Duration

Vital parameters including systolic and diastolic blood pressure, heart rate, respiration rate, and temperature were recorded. The number of participants with potentially clinically concern value of any vital parameter at any visit were reported.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Trends in Vital Signs Over the Period of Study Duration
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Number of Participants With Clinically Significant Trends in Vital Signs Over the Period of Study Duration000
PrimaryNumber of Participants With Normal and Abnormal ECG Findings

12-lead ECGs was obtained during the study using an ECG machine and performed with the participant in a semi-supine position rested in this position for at least 10 minutes beforehand. Measurements deviated substantially from previous readings were repeated immediately. Number of participants with normal and abnormal ECG findings were reported.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Number of Participants With Normal and Abnormal ECG Findings
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Baseline, Pre-dose 1, Normal444
Baseline, Pre-dose 1, Unable to evaluate001
Baseline, Pre-dose 1, Abnormal100
Baseline, Pre-dose 2, Normal445
Baseline, Pre-dose 2, Abnormal100
Baseline, Pre-dose 3, Normal445
Baseline, Pre-dose 3, Abnormal100
Baseline, Post-dose , Normal434
Baseline, Post-dose , Abnormal111
On IV Therapy (Day 4), Pre-dose, Normal445
On IV Therapy (Day 4), Pre-dose, Abnormal100
On IV Therapy (Day 4), Post-dose, Normal545
Early Follow-up535
PrimaryLaboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration

Absolute mean hemoglobin values recorded over the period of duration were reported.

Time frame:
Up to Day 42
Reported as:
Mean · Gram per Litre
Laboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration
Gram per LitreGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Baseline (Day 1)142.2 ± 8.76121.5 ± 12.23125.0 ± 14.85
On IV Therapy (Day 3)134.4 ± 13.61112.3 ± 16.30137.3 ± 19.64
On IV Therapy (Day 5)127.2 ± 14.79120.7 ± 11.02131.0 ± 18.63
On IV Therapy (Day 8)148.0 ± NA132.0 ± NA143.0 ± NA
On IV Therapy (Day 11)97.0 ± NA——
End Of IV Therapy126.2 ± 23.35123.8 ± 9.88130.8 ± 20.22
Haematology Safety131.4 ± 15.21118.0 ± 9.93138.6 ± 14.72
Test of cure131.0 ± 25.26116.0 ± 5.77138.2 ± 11.52
Early Follow up125.5 ± 31.16121.5 ± 3.54138.5 ± 10.54
Late Follow up133.2 ± 19.38126.5 ± 0.71146.8 ± 17.25
PrimaryLaboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration

Absolute mean reticulocytes values recorded over the period of duration were reported.

Time frame:
Up to 42 days
Reported as:
Mean · Trillion cells per Litre
Laboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration
Trillion cells per LitreGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Baseline (Day 1)0.0589 ± 0.018390.0573 ± 0.007610.0810 ± 0.02547
On IV Therapy (Day 3)0.0487 ± 0.018740.0638 ± 0.030740.0725 ± 0.02418
On IV Therapy (Day 5)0.0580 ± 0.023770.0480 ± 0.005150.0870 ± 0.02888
On IV Therapy (Day 8)0.0077 ± NA0.0444 ± NA0.0650 ± NA
On IV Therapy (Day 11)0.0335 ± NA——
End Of IV Therapy0.0564 ± 0.029190.0602 ± 0.018990.0872 ± 0.02792
Haematology Safety0.0640 ± 0.024060.0478 ± 0.019370.0815 ± 0.03405
Test Of Cure0.0959 ± 0.012600.0860 ± 0.017640.0846 ± 0.01270
Early Follow up0.0842 ± 0.025590.0769 ± 0.005370.0796 ± 0.02874
Late Follow up0.1046 ± 0.029450.0870 ± 0.010180.0828 ± 0.01431
PrimaryMean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop

Participants in whom the hemoglobin level dropped by more than 30% from Baseline that was not attributable to acute blood loss were recorded and immediately withdrawn from study treatment. Baseline assessments were recorded on Visit 1 (Day 1) and used as Baseline values. The change from Baseline was calculated by subtracting the Baseline values from Day 42 values. If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing. The mean change from Baseline in hemoglobin for participants with significant hemoglobin drop were reported.

Time frame:
Baseline (Day 1) and up to Day 42
Reported as:
Mean · grams/L
Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop
grams/LGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
On IV Therapy, Day 3-7.8 ± 18.07-13.3 ± 8.620.0 ± 9.90
On IV Therapy, Day 5-15.0 ± 18.881.5 ± 3.54-1.7 ± 8.62
On IV Therapy, Day 83.0 ± NA-6.0 ± NA—
On IV Therapy, Day 11-58.0 ± NA——
End of IV Therapy-16.0 ± 28.88-0.7 ± 3.79-2.3 ± 3.79
Hematology Safety-10.8 ± 22.48-8.3 ± 13.8010.0 ± 8.72
Test for Cure-13.3 ± 32.09-8.7 ± 15.9511.0 ± 10.58
Early Follow-up-16.5 ± 39.316.0 ± 5.661.5 ± 7.78
Late Follow-up-9.0 ± 25.8211.0 ± 9.9020.0 ± 2.65
PrimaryNumber of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Intent to Treat (MITT) Population

Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.

Time frame:
Day 5 to 9 post IV therapy
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Intent to Treat (MITT) Population
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Test of Cure Clinical Success314
Test of Cure Clinical Failure110
SecondaryNumber of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Evaluable Population.

Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.

Time frame:
Day 5 to 9 post IV therapy
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Evaluable Population.
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Test of Cure Clinical Success314
End of IV Clinical Failure110
SecondaryNumber of Participants With Microbiological Response in MITT Population

Microbiological Response at End of IV Therapy was assessed as Microbiological Success (MS) or Microbiological Failure (MF). MS was categorized as microbiological eradication (ME) and presumed microbiological eradication (PME). MF was categorized as microbiological persistence (MP), presumed microbiological persistence (PMP), unable to determine, new infection and colonization. Number of participants with microbiological response in MITT population were reported.

Time frame:
End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Response in MITT Population
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
End of IV Therapy, MS, PME314
End of IV Therapy, MF, MP010
End of IV Therapy, MF, PMP100
Test of Cure, MS, PME314
Test of Cure, MF, PMP110
Late follow-up, MS, PME314
Late follow-up, MF, PMP110
SecondaryNumber of Participants With Microbiological Response in Microbiological Evaluable Population

Microbiological Response at End of IV Therapy was assessed as MS or MF. MS was categorized as ME and PME. MF was categorized as MP and PMP, unable to determine, new infection and colonization. Number of participants with microbiological response in microbiological evaluable population were reported.

Time frame:
End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Response in Microbiological Evaluable Population
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
End of IV Therapy, MS, PME314
End of IV Therapy, MF, MP010
End of IV Therapy, MF, PMP100
Test of Cure, MS, PME314
Test of Cure, MF, PMP110
Late follow-up, MS, PME314
Late follow-up, MF, PMP100
SecondaryNumber of Participants With Clinical Response in Microbiological Evaluable Population

Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.

Time frame:
End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response in Microbiological Evaluable Population
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
End of IV Therapy, Clinical Success314
End of IV Therapy, Clinical Failure110
Late follow-up, Follow-up Clinical Success314
Late follow-up, End of IV Clinical Failure100
SecondaryNumber of Participants With Clinical Response in MITT Population

Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.

Time frame:
End of IV therapy (0-24 hours post-therapy) and Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response in MITT Population
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
End of IV Therapy, Clinical Success,314
End of IV Therapy, Clinical Failure110
Late follow-up, Follow-up Clinical Success314
Late follow-up, End of IV Clinical Failure110
SecondaryNumber of Participants With Therapeutic Response in Microbiological Evaluable Population

Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.

Time frame:
End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response in Microbiological Evaluable Population
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
End of IV Therapy, Therapeutic Success314
End of IV Therapy, Therapeutic Failure110
Test of Cure, Therapeutic Success314
Test of Cure, Therapeutic Failure110
Late Follow-up, Therapeutic Success314
Late Follow-up, Therapeutic Failure110
SecondaryNumber of Participants With Therapeutic Response in MITT Population

Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.

Time frame:
End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response in MITT Population
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
End of IV Therapy, Therapeutic Success314
End of IV Therapy, Therapeutic Failure110
Test of Cure, Therapeutic Success314
Test of Cure, Therapeutic Failure110
Late Follow-up, Therapeutic Success314
Late Follow-up, Therapeutic Failure110
SecondaryMaximum Plasma Concentration (Cmax) of GSK2251052

Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for pharmacokinetics (PK) analysis was not collected.

Time frame:
Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryArea Under the Concentration Time Curve (AUC) of GSK2251052

AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryTime to Cmax (Tmax) of GSK2251052

Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryCmax of GSK2251052 Using Non-intensive PK Sampling

Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryAUC of GSK2251052 Using Non-intensive PK Sampling

AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryTmax of GSK2251052 Using Non-intensive PK Sampling

Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryCmax of GSK2251052 Using Intensive PK Sampling

Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryAUC of GSK2251052 Using Intensive PK Sampling

AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryTmax of GSK2251052 Using Intensive PK Sampling

Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.

Time frame:
Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

No measurements were reported for this outcome.

Adverse events

Collected over AEs were reported up to Late Follow-up visit (Day 42). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK2251052 750 mg0/5 (0%)2/5 (40%)4/5 (80%)
GSK2251052 1500 mg0/4 (0%)3/4 (75%)4/4 (100%)
Meropenem 1g0/5 (0%)0/5 (0%)3/5 (60%)
Most frequent serious events
Most frequent serious events
EventGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
Abdominal abscessInfections and infestations0/52/40/5
Blood creatinine increasedInvestigations0/51/40/5
Bile duct stoneHepatobiliary disorders0/51/40/5
Pelvic abscessInfections and infestations1/50/40/5
Haemoglobin decreasedInvestigations1/50/40/5
Pancreatitis acuteGastrointestinal disorders1/50/40/5
Most frequent other events
Showing 10 of 38
Most frequent other events
EventGSK2251052 750 mgGSK2251052 1500 mgMeropenem 1g
PyrexiaGeneral disorders0/52/41/5
DiarrhoeaGastrointestinal disorders1/51/41/5
DyspepsiaGastrointestinal disorders0/51/40/5
Infusion site painGeneral disorders0/51/40/5
Blood creatinine increasedInvestigations0/51/40/5
Electrolyte imbalanceMetabolism and nutrition disorders1/51/40/5
HypokalaemiaMetabolism and nutrition disorders0/51/40/5
HypophosphataemiaMetabolism and nutrition disorders0/51/40/5
DizzinessNervous system disorders0/51/40/5
CoughRespiratory, thoracic and mediastinal disorders0/51/40/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK2251052 750 mgGSK2251052 1500 mgMeropenem 1 gTotal
Mean34.0 ± 15.0541.3 ± 13.6534.6 ± 10.3136.3 ± 12.49
Sex: Female, Male
Sex: Female, Male(Participants)GSK2251052 750 mgGSK2251052 1500 mgMeropenem 1 gTotal
Female1113
Male43411
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK2251052 750 mgGSK2251052 1500 mgMeropenem 1 gTotal
African American/African Heritage1012
Asian - Central/South Asian Heritage0011
Asian - East Asian Heritage0101
White - White/Caucasian/European43310
09

Study locations

31 sites
  • GSK Investigational Site
    Mobile, Alabama 36617, United States
  • GSK Investigational Site
    Long Beach, California 90822, United States
  • GSK Investigational Site
    Torrance, California 90509, United States
  • GSK Investigational Site
    Jacksonville, Florida 32209, United States
  • GSK Investigational Site
    Council Bluffs, Iowa 51503, United States
  • GSK Investigational Site
    Topeka, Kansas 66604, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89109, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    Columbus, Ohio 43215, United States
  • GSK Investigational Site
    Lima, Ohio 45801, United States
  • GSK Investigational Site
    Richmond, Virginia 23298, United States
  • GSK Investigational Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • GSK Investigational Site
    Trois-Rivières, Quebec G8Z 3R9, Canada
  • GSK Investigational Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • GSK Investigational Site
    Praha 10, 100 34, Czechia
  • GSK Investigational Site
    Praha 10, 10034, Czechia
  • GSK Investigational Site
    Limoges, 87042, France
  • GSK Investigational Site
    Nîmes cedex 9, 30029, France
  • GSK Investigational Site
    Strasbourg, 67200, France
  • GSK Investigational Site
    Verona, Veneto 37134, Italy
  • GSK Investigational Site
    Irkutsk, 664079, Russian Federation
  • GSK Investigational Site
    Perm, 614036, Russian Federation
  • GSK Investigational Site
    Perm, 614068, Russian Federation
  • GSK Investigational Site
    Smolensk, 214019, Russian Federation
  • GSK Investigational Site
    St. Petersburgh, 192242, Russian Federation
  • GSK Investigational Site
    Alicante, 03010, Spain
  • GSK Investigational Site
    Elche (Alicante), 03203, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Pama de Mallorca, 07010, Spain
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Mar 2012, 5 months.

Results were first posted in Nov 2017, 5 years 8 months after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jun 27, 2011
StartActual
Oct 3, 2011
Primary completionActual
Mar 5, 2012
CompletionActual
Mar 5, 2012
Results delay requested
Nov 15, 2012
Results first posted
Nov 29, 2017
Last update
Nov 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01381562
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Oct 3, 2011
Primary completion
Mar 5, 2012
Completion
Mar 5, 2012
Results posted
Nov 29, 2017
Last update
Nov 29, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion